Skip to search formSkip to main contentSkip to account menu

nebicapone

Known as: 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Acetophenones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Review
2012
Review
2012
A Systematic Review of Catechol-O-Methyltransferase Inhibitors: Efficacy and Safety in Clinical Practice
&NA;Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease… 
2011
2011
In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs
Objectives  Patients with Parkinson's disease can benefit from controlled released levodopa dosage forms since there is a clear… 
Review
2010
Review
2010
Toxicology and safety of COMT inhibitors.
  • K. Haasio
  • International review of neurobiology
  • 2010
  • Corpus ID: 21860089
Review
2010
Review
2010
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
  • S. Kaakkola
  • International review of neurobiology
  • 2010
  • Corpus ID: 883048
2010
2010
A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
To determine the efficacy, safety and tolerability of nebicapone, a new catechol‐O‐methyltransferase inhibitor for the treatment… 
2008
2008
Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease
Objective: To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa… 
Review
2007
Review
2007
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent… 
2006
2006
Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is… 
2002
2002
Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor.
BIA 3-202, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 3, is a novel, reversible, and tight-binding peripheral inhibitor of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)